LANTERN PHARMA INC
LTRNNASDAQTrading Snapshot
- Day Range
- $0.23 β $0.26
- 52-Week Range
- $0.23 β $4.34
- Volume (shares)
- 234,152
- Avg Volume (shares)
- β
- Shares Outstanding
- 14.9M
- Next Earnings
- 2027-03-29
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- -0.2
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.02
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1.1%
LANTERN PHARMA INC
LTRNAbout LANTERN PHARMA INC
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

Lantern Pharma Reports Third Quarter 2026 Financial Results and Provides Business Updates
DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports Third Quarter 2026 Financial Results and Provides Business Updates.

Lantern Pharma Announces Peer-Reviewed Publication of Phase 1a LP-184 Data in Recurrent Glioblastoma, Supporting a Phase 1b/2a Combination Trial with Spironolactone
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, and its wholly owned subsidiary Starlight Therapeutics today announced the publication of Phase 1a clini

Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONICβ’ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received regulatory and IRB approvals in

Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering.

Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN) (βLanternβ, the βCompanyβ or βweβ), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology t

Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development Transcript
Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development Transcript